Dr. Agarwal's Health Care Limited has informed the Exchange about Presentation
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Agarwal's Health Care Limited (AHCL) has filed an investor presentation detailing the proposed merger of its subsidiary Dr. Agarwal's Eye Hospital Limited (AEHL) into itself, creating a single listed entity housing all of Dr. Agarwal's operations. AEHL shareholders (other than AHCL) will receive 23 AHCL shares for every 2 AEHL shares held, implying a 15% premium to AEHL's 10-day VWAP; additionally, AEHL will allot ₹70 Cr to AHCL via a preferential issue (~2.7% of post-issue capital). Post-merger shareholding will be 64.5% promoters, 30.9% AHCL public, and 4.6% AEHL public. The merger, targeted for completion by Q2 FY27, is expected to be EPS accretive from year one and is subject to shareholder, stock exchange, SEBI, and NCLT approvals.
Shareholders of both companies gain a simplified group structure with unified governance and better capital allocation flexibility, while AHCL standalone investors should see EPS accretion from year one of implementation. Near-term, the stock may react to the swap ratio and timeline; overhang from regulatory approvals (~12–14 months) remains the key risk.